Answers are grounded in this paper and cite their sources.
tumor-specific vaccines to elicit adaptive immunity. Oncolytic herpes simplex viruses (oHSVs) are among the most widely studied OVs for the treatment of solid malignancies, and Amgen's oHSV Imlygic® for the treatment of melanoma is the only OV approved in major markets. Here we describe important biological features of HSV that make it an attractive OV, clinical experience with HSV-based vectors, and strategies to increase applicability to cancer treatment.
No takes yet. Share an insight, caveat, or question.
Glorioso et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: